Fabio Guolo, MD, of the University of Genoa, Genoa, Italy, spoke to us at the 23rd Congress of the European Hematology Association (EHA) 2018, held in Stockholm, Sweden, about how measurable residual disease (MRD) can be used to inform treatment in acute myeloid leukemia (AML). He uses acute lymphoblastic leukemia (ALL) as an example, where using MRD to inform allocation of allogenic stem cell transplants has drastically improved patient outcomes, and emphasizes the potential for a similar application in AML, though the use of MRD in AML is still a few steps behind that in ALL.
Using MRD to inform allocation of stem cell transplants in ALL and AML
